{"id":"https://openalex.org/W7221813655","doi":"https://doi.org/10.3389/fimmu.2026.1903377","title":"Case Report: Upadacitinib for Acrodermatitis continua of Hallopeau: a case series with literature review","display_name":"Case Report: Upadacitinib for Acrodermatitis continua of Hallopeau: a case series with literature review","publication_year":2026,"publication_date":"2026-10-14","ids":{"openalex":"https://openalex.org/W7221813655","doi":"https://doi.org/10.3389/fimmu.2026.1903377","pmid":"https://pubmed.ncbi.nlm.nih.gov/42953180","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13713813"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2026.1903377","doi":"https://doi.org/10.3389/fimmu.2026.1903377","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1903377","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1903377/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1903377/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5130410499","display_name":"Yu-Ting Gan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280124","display_name":"Chongqing College of Traditional Chinese Medicine","ror":"https://ror.org/02fpqkk77","country_code":"CN","type":"education","lineage":["https://openalex.org/I4405280124"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yu-ting Gan","raw_affiliation_strings":["Chongqing University of Chinese Medicine","Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chongqing University of Chinese Medicine","institution_ids":[]},{"raw_affiliation_string":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","institution_ids":["https://openalex.org/I4405280124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5158689308","display_name":"Shi Yan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280124","display_name":"Chongqing College of Traditional Chinese Medicine","ror":"https://ror.org/02fpqkk77","country_code":"CN","type":"education","lineage":["https://openalex.org/I4405280124"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shi Yan","raw_affiliation_strings":["Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","institution_ids":["https://openalex.org/I4405280124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138675905","display_name":"Wei-na Xie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280124","display_name":"Chongqing College of Traditional Chinese Medicine","ror":"https://ror.org/02fpqkk77","country_code":"CN","type":"education","lineage":["https://openalex.org/I4405280124"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wei-na Xie","raw_affiliation_strings":["Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","institution_ids":["https://openalex.org/I4405280124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100330550","display_name":"Yi Liu","orcid":"https://orcid.org/0000-0002-5821-5739","observed_orcids":["https://orcid.org/0000-0002-5821-5739"]},"institutions":[{"id":"https://openalex.org/I4405280124","display_name":"Chongqing College of Traditional Chinese Medicine","ror":"https://ror.org/02fpqkk77","country_code":"CN","type":"education","lineage":["https://openalex.org/I4405280124"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yi Liu","raw_affiliation_strings":["Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","institution_ids":["https://openalex.org/I4405280124"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5158740310","display_name":"Feng-lin Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280124","display_name":"Chongqing College of Traditional Chinese Medicine","ror":"https://ror.org/02fpqkk77","country_code":"CN","type":"education","lineage":["https://openalex.org/I4405280124"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Feng-lin Chen","raw_affiliation_strings":["Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","institution_ids":["https://openalex.org/I4405280124"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5158740310"],"corresponding_institution_ids":["https://openalex.org/I4405280124"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.80956189,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1903377","last_page":"1903377"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9272000193595886,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9272000193595886,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.027499999850988388,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12355","display_name":"Genetic and rare skin diseases.","score":0.004999999888241291,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acrodermatitis-continua-of-hallopeau","display_name":"acrodermatitis continua of Hallopeau","score":0.9639999866485596},{"id":"https://openalex.org/keywords/upadacitinib","display_name":"upadacitinib","score":1.0},{"id":"https://openalex.org/keywords/jak1-inhibitor","display_name":"JAK1 inhibitor","score":0.9049999713897705},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.4050000011920929},{"id":"https://openalex.org/keywords/disease-related-quality-of-life","display_name":"disease-related quality of life","score":0.8180000185966492},{"id":"https://openalex.org/keywords/nail-lesions","display_name":"nail lesions","score":0.6129999756813049},{"id":"https://openalex.org/keywords/pustular-dermatosis","display_name":"pustular dermatosis","score":0.734000027179718},{"id":"https://openalex.org/keywords/inflammatory-skin-diseases","display_name":"inflammatory skin diseases","score":0.5360000133514404}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9265999794006348},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.6919999718666077},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6241000294685364},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.49309998750686646},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4876999855041504},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48080000281333923},{"id":"https://openalex.org/C2779121184","wikidata":"https://www.wikidata.org/wiki/Q1166142","display_name":"Erythema","level":2,"score":0.46369999647140503},{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.4377000033855438},{"id":"https://openalex.org/C2780538096","wikidata":"https://www.wikidata.org/wiki/Q4675757","display_name":"Acrodermatitis","level":3,"score":0.4101000130176544},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3686999976634979},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.3580000102519989},{"id":"https://openalex.org/C2778758164","wikidata":"https://www.wikidata.org/wiki/Q430438","display_name":"Onycholysis","level":3,"score":0.35569998621940613},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.33820000290870667},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.33660000562667847},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.33169999718666077},{"id":"https://openalex.org/C3020110884","wikidata":"https://www.wikidata.org/wiki/Q695416","display_name":"Outpatient clinic","level":2,"score":0.3239000141620636},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.29420000314712524},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.2734000086784363},{"id":"https://openalex.org/C2992053201","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Clinical efficacy","level":2,"score":0.2711000144481659}],"mesh":[{"descriptor_ui":"D000075242","descriptor_name":"Janus Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000169","descriptor_name":"Acrodermatitis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D000169","descriptor_name":"Acrodermatitis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2026.1903377","doi":"https://doi.org/10.3389/fimmu.2026.1903377","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1903377","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1903377/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13713813","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13713813/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13713813/pdf/fimmu-17-1903377.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:42953180","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42953180","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:14da00a29b6e492a86764373c7365726","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/14da00a29b6e492a86764373c7365726","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2026.1903377","doi":"https://doi.org/10.3389/fimmu.2026.1903377","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1903377","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1903377/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[{"id":"https://openalex.org/G504305494","display_name":null,"funder_award_id":"CSTB2024NSCQ","funder_id":"https://openalex.org/F4320323172","funder_display_name":"Natural Science Foundation of Chongqing"},{"id":"https://openalex.org/G6238965037","display_name":null,"funder_award_id":"82405590","funder_id":"https://openalex.org/F4320321001","funder_display_name":"National Natural Science Foundation of China"},{"id":"https://openalex.org/G9000850667","display_name":null,"funder_award_id":"CSTB2024NSCQ-MSX1075","funder_id":"https://openalex.org/F4320323172","funder_display_name":"Natural Science Foundation of Chongqing"}],"funders":[{"id":"https://openalex.org/F4320321001","display_name":"National Natural Science Foundation of China","ror":"https://ror.org/01h0zpd94"},{"id":"https://openalex.org/F4320323172","display_name":"Natural Science Foundation of Chongqing","ror":"https://ror.org/01h0zpd94"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7221813655.pdf","grobid_xml":"https://content.openalex.org/works/W7221813655.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W1974634839","https://openalex.org/W2412454729","https://openalex.org/W2895207293","https://openalex.org/W2931858056","https://openalex.org/W2967470337","https://openalex.org/W3041662907","https://openalex.org/W3134754988","https://openalex.org/W3184051397","https://openalex.org/W4223594625","https://openalex.org/W4287219590","https://openalex.org/W4383872067","https://openalex.org/W4389832829","https://openalex.org/W4392916001","https://openalex.org/W4393119984","https://openalex.org/W4403063649","https://openalex.org/W4404070498","https://openalex.org/W4404590249","https://openalex.org/W4404797401","https://openalex.org/W4409726833","https://openalex.org/W4410382119","https://openalex.org/W4411021306","https://openalex.org/W4413380498","https://openalex.org/W4414625580","https://openalex.org/W4415362319","https://openalex.org/W4416624752","https://openalex.org/W4416892408","https://openalex.org/W4417419156","https://openalex.org/W7127934691","https://openalex.org/W7131363328","https://openalex.org/W7133309560"],"related_works":["https://openalex.org/W7170837651","https://openalex.org/W3041662907","https://openalex.org/W7160521283","https://openalex.org/W2913495210","https://openalex.org/W2950899535","https://openalex.org/W4413380498","https://openalex.org/W4403063649","https://openalex.org/W4410101444","https://openalex.org/W1974634839","https://openalex.org/W2064482888"],"abstract_inverted_index":{"Background:":[0],"Acrodermatitis":[1],"continua":[2],"of":[3,115,183,318],"Hallopeau":[4],"(ACH)":[5],"is":[6,226,297],"a":[7,41,106],"relatively":[8],"rare":[9],"chronic":[10],"skin":[11,53,161],"disorder":[12],"often":[13],"associated":[14],"with":[15,75,187,249],"immune":[16],"system":[17],"abnormalities.":[18],"Conventional":[19],"systemic":[20],"therapies":[21],"and":[22,27,100,117,162,185,204,228,286,299,315],"biologics":[23],"have":[24],"limited":[25,282],"efficacy":[26,275],"are":[28,309],"prone":[29],"to":[30,83,119,170,283,311],"relapse,":[31],"highlighting":[32],"the":[33,316],"urgent":[34],"need":[35],"for":[36,155],"new":[37],"treatment":[38,96],"options.":[39],"Upadacitinib,":[40],"highly":[42],"selective":[43],"JAK1":[44],"inhibitor,":[45],"has":[46,60],"shown":[47],"promising":[48,274],"results":[49],"in":[50,58,112,125,160,247,276,294],"various":[51],"inflammatory":[52],"diseases;":[54],"however,":[55],"its":[56],"application":[57],"ACH":[59,72],"rarely":[61],"been":[62],"reported.":[63],"Methods:":[64],"A":[65],"retrospective":[66,239],"analysis":[67],"was":[68,110,173],"conducted":[69],"on":[70,122],"6":[71,129,147],"patients":[73,130,217,251,296],"treated":[74],"upadacitinib":[76,152,242],"at":[77],"our":[78],"outpatient":[79],"clinic":[80],"from":[81,168,292],"2023":[82],"2025.":[84],"Clinical":[85],"data,":[86],"including":[87],"demographics,":[88],"disease":[89,142],"duration,":[90,97],"sites":[91],"involved,":[92],"prior":[93],"treatments,":[94],"dosage,":[95],"DLQI":[98,166,259],"scores,":[99],"adverse":[101,212],"events,":[102],"were":[103],"collected.":[104],"Meanwhile,":[105],"narrative":[107],"literature":[108,265],"search":[109],"performed":[111],"PubMed,":[113],"Web":[114],"Science,":[116],"Embase":[118],"identify":[120],"studies":[121,308],"JAK":[123,269],"inhibitors":[124],"ACH.":[126],"Results:":[127],"Among":[128],"(2":[131],"males,":[132],"4":[133],"females;":[134],"mean":[135,141,165],"age":[136],"42.8":[137],"years,":[138,145],"range":[139,146],"22-59;":[140],"duration":[143],"1.9":[144],"months-4":[148],"years),":[149],"all":[150],"received":[151],"15":[153,243],"mg/day":[154,244],"3-13":[156],"months.":[157],"Most":[158],"improved":[159,221],"nail":[163,188],"lesions;":[164],"decreased":[167],"14.0":[169],"6.0.":[171],"Response":[172,289],"assessed":[174],"primarily":[175],"by":[176,232,303],"clinical":[177,194,199,206,253,262],"signs:":[178],"complete":[179,200],"response":[180,191,201,208],"required":[181,192],"resolution":[182],"pustules":[184],"erythema":[186],"improvement;":[189],"partial":[190,207],"\u226550%":[193],"improvement.":[195],"One":[196],"patient":[197],"had":[198,257],"(DLQI":[202,209],"71%)":[203],"another":[205],"42%).":[210],"No":[211],"events":[213],"occurred.":[214],"Notably,":[215],"3":[216],"who":[218],"failed":[219],"tofacitinib":[220,293],"after":[222,290],"switching,":[223],"though":[224],"this":[225,237],"preliminary":[227,298],"may":[229,300],"be":[230,301],"confounded":[231,302],"cumulative":[233,304],"exposure.":[234],"Conclusion:":[235],"In":[236],"small":[238,287],"case":[240,284],"series,":[241],"appeared":[245],"effective":[246],"ACH,":[248,277],"most":[250],"showing":[252],"improvement,":[254],"although":[255],"two":[256],"subthreshold":[258],"improvement":[260],"despite":[261],"response.":[263],"The":[264],"review":[266],"indicates":[267],"that":[268],"inhibitors,":[270],"particularly":[271],"upadacitinib,":[272],"show":[273],"but":[278],"current":[279],"evidence":[280],"remains":[281],"reports":[285],"series.":[288],"switching":[291],"three":[295],"exposure;":[305],"larger":[306],"prospective":[307],"needed":[310],"confirm":[312],"efficacy,":[313],"safety,":[314],"value":[317],"switching.":[319]},"counts_by_year":[],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2026-10-15T00:00:00"}